Drug-induced QT prolongation: An update

Annals of Noninvasive Electrocardiology

Volumn 11, Issue 1, 2006, Pages 1-2

  Moss, Arthur J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; CALCIUM CHANNEL; CISAPRIDE; FEXOFENADINE; GASTROINTESTINAL AGENT; MOXIFLOXACIN; PROKINETIC AGENT; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TERFENADINE;

CHANNEL GATING; DRUG APPROVAL; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG SCREENING; EDITORIAL; ELECTROCARDIOGRAM; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; SYNCOPE;

ELECTROCARDIOGRAPHY; FLUOROQUINOLONES; HUMANS; LONG QT SYNDROME; QUINIDINE; TERFENADINE;

EID: 33644980402     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2006.00086.x     Document Type: Editorial

References (8)

1. Moss AJ Measurement of the QT interval and the risk associated with QTc interval prolongation: A review Am J Cardiol 1993 72 23B 25B
2. Echt DS Liebson PR Mitchell LB et al Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial N Engl J Med 1991 324 781 788
3. Monahan BP Ferguson CL Killeavy ES et al Torsades de pointes occurring in association with terfenadine use JAMA 1990 264 2788 2790
4. Moss AJ Zareba W Benhorin J et al ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: Task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization Ann Noninvasive Electrocardiol 2001 6 333 341
5. FDA Talk Paper Janssen stops marketing cisapride in the US 2000
6. FDA U.S. Department of Health and Human Services Food and Drug Administration The non-clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhyhmic drugs 2005
7. Mitcheson JS Chen J Lin M et al A structural basis for drug-induced long QT syndrome Proc Natl Acad Sci U S A 2000 97 12329 12333
8. Moss AJ Zareba W Kaufman ES et al Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel Circulation 2002 105 794 799